苯海拉明作为慢性阿片类药物使用患者结肠镜检查辅助镇静剂的应用:一项随机对照试验
这项随机双盲安慰剂对照试验纳入慢性阿片类药物使用并接受结肠镜检查的患者,比较静脉苯海拉明50 mg(n=61)与安慰剂(n=58)辅助芬太尼和咪达唑仑的镇静效果。结果显示两组芬太尼和咪达唑仑用量无差异,但苯海拉明组医生和护士的镇静评分及患者疼痛、遗忘评分更优,不良事件未增加。
要点
- 苯海拉明不减少慢性阿片类药物使用患者结肠镜检查的芬太尼和咪达唑仑用量。
- 苯海拉明组医生镇静评分和护士镇静评分均优于安慰剂组。
- 苯海拉明组患者疼痛评分和遗忘评分优于安慰剂组,不良事件未增加。
核心结论
- 在慢性阿片类药物治疗患者中,给予苯海拉明不能降低操作镇静剂的剂量,但可改善镇静质量且不增加不良事件数量。
研究设计与样本
- 随机双盲安慰剂对照试验,纳入慢性阿片类药物使用并接受结肠镜检查的患者,苯海拉明组n=61,安慰剂组n=58。
- 苯海拉明组静脉给予苯海拉明50 mg,安慰剂组给予安慰剂,两组均联合芬太尼和咪达唑仑。
主要发现
- 芬太尼用量苯海拉明组125.4 ± 56.2 μg vs 安慰剂组126.9 ± 53.5 μg,P = .88。
- 咪达唑仑用量苯海拉明组4.9 ± 2.1 mg vs 安慰剂组5 ± 1.9 mg,P = .79。
- 医生镇静评分苯海拉明组6.2 ± 1.1 vs 安慰剂组5.3 ± 1.2,P = .0002,差异有统计学意义且有利于苯海拉明组。
- 护士镇静评分苯海拉明组5.6 ± 1.5 vs 安慰剂组5.1 ± 1.4,P = .04,差异有统计学意义且有利于苯海拉明组。
- 患者疼痛评分苯海拉明组2.05 ± 2.17 vs 安慰剂组3.09 ± 3.95,P = .047;遗忘评分苯海拉明组7.8 ± 3.4 vs 安慰剂组6.5 ± 3.8,P = .047,均有利于苯海拉明组。
关键数值与推荐
- 定性评估显示两组间无显著差异。
- 诱导时间(P = .86)、操作时长(P = .98)和恢复时间(P = .16)两组间无差异。
- 低血压事件在安慰剂组更常见(P = .027)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Chronic opioid use increases tolerance to sedatives. Diphenhydramine is recommended for difficult-to-sedate patients during endoscopic procedures. We hypothesized that the addition of diphenhydramine to midazolam and fentanyl would improve objective and subjective measures of procedural sedation. METHODS: This randomized, double-blind, placebo-controlled trial included patients on chronic opioids undergoing colonoscopy. Patients were randomized to receive 50 mg of diphenhydramine intravenously (n = 61) or placebo (n = 58), in addition to fentanyl and midazolam. Baseline characteristics, amount of fentanyl and midazolam, procedure times, and adverse events were recorded. Quality of sedation was assessed by the physician and nurse. Patients rated pain and amnesia on a 10-point scale. RESULTS: There was no difference in amounts of fentanyl (125.4 ± 56.2 μg vs 126.9 ± 53.5 μg, P = .88) and midazolam (4.9 ± 2.1 mg vs 5 ± 1.9 mg, P = .79) used. The mean sedation scores from the physician (6.2 ± 1.1 vs 5.3 ± 1.2, P =.0002) and nurses (5.6 ± 1.5 vs 5.1 ± 1.4, P =.04) were statistically significant in favor of the diphenhydramine arm. Patient scores for pain (2.05 ± 2.17 vs 3.09 ± 3.95, P =.047) and amnesia (7.8 ± 3.4 vs 6.5 ± 3.8, P =.047) favored the group that received diphenhydramine. Qualitative assessment showed no significant difference between the groups. There was no difference in induction time (P = .86), procedure duration (P = .98), or recovery time (P = .16). Hypotensive episodes were more common in the placebo group (P = .027). CONCLUSIONS: In patients on chronic opioid therapy, administration of diphenhydramine does not allow for lower doses of procedural sedatives but improves quality of sedation without increasing the number of adverse events. (Clinical trial registration number: NCT T01967433.).
引用
- Nusrat S, Madhoun MF, Tierney WM, et al. Use of diphenhydramine as an adjunctive sedative for colonoscopy in patients on chronic opioid therapy: a randomized controlled trial. Gastrointest Endosc. 2018. PMID: 29689257. doi:10.1016/j.gie.2018.04.2342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。